One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Apyx Medical Corporation
APYX · NMS · Healthcare · Medical Devices
Current price
$2.94
52-week range
$2.25 - $5.08
Market cap
$123.84M
Balance sheet
Distressed
-1.15x Concerning
Net debt $12.01M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 12.7% last year.
- Risk Return on equity was -90.7% last year — the company lost money on shareholders' equity.
What this company does
Apyx Medical Corporation
Apyx Medical Corporation makes special tools for surgeons that use a type of energy to help cut and seal tissue. Most of their money comes from selling these tools to doctors and hospitals, which helps them keep their business running and hopefully grow. This matters because if their tools are popular and people keep buying them, the company can make more money.
How the company got here
Apyx Medical Corporation, originally known as Bovie Medical Corporation, was founded in 1982 and is based in Clearwater, Florida. The company underwent a significant name change in January 2019 to Apyx Medical Corporation, reflecting a strategic shift. This evolution has positioned the company as a player in the energy technology space, focusing on developing and manufacturing advanced medical devices.
What it actually does
Apyx Medical designs, develops, and sells specialized equipment that uses energy to perform medical procedures. Think of it like a high-tech tool that doctors use to precisely cut or seal tissue during surgery. Their main technology uses helium and radiofrequency energy to help surgeons work more effectively on soft tissues, both in open surgeries and less invasive procedures.
Surgical Aesthetics
This part of Apyx Medical focuses on the cosmetic surgery market, selling products under the Renuvion brand name. These devices use a combination of helium and radiofrequency energy to help tighten skin and improve the appearance of certain areas. Essentially, it's a tool used by cosmetic surgeons to achieve aesthetic results for their patients, often after procedures like liposuction or for general skin laxity.
Original Equipment Manufacturing (OEM)
In this segment, Apyx Medical acts as a manufacturer for other companies. They develop and produce generators and related accessories that other medical device companies can then brand and sell as their own. This business line leverages Apyx's expertise in energy-based technology to create products for a wider market through partnerships, contributing to the company's overall revenue stream.
What management is betting on now
Management is focused on expanding the reach and application of their helium plasma technology. They aim to grow both their Renuvion brand in the cosmetic surgery space and their J-Plasma brand in hospital surgical settings. A key priority is also to strengthen their OEM business by continuing to develop and manufacture advanced energy-based devices for other medical companies, diversifying their revenue sources and leveraging their technological capabilities.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-3.18M
FY2025 Q1
$-757.00K
FY2025 Q2
$-1.50M
FY2025 Q3
$-4.05M
FY2025 Q4
$-2.81M
FY2026 Q1
$-632.00K
FY2026 Q2
$-3.56M
FY2026 Q3
$-1.90M
Revenue
$14.03M
Net income
$-1.78M
Diluted EPS
—
Operating cash flow
$-1.63M
Free cash flow
$-1.90M
Fetching…
Sources
Revenue
$13.88M
Net income
$-3.24M
Diluted EPS
—
Operating cash flow
$-3.49M
Free cash flow
$-3.56M
Fetching…
Sources
Revenue
$12.49M
Net income
$-2.11M
Diluted EPS
—
Operating cash flow
$-572.00K
Free cash flow
$-632.00K
Fetching…
Sources
Revenue
$19.16M
Net income
$-1.30M
Diluted EPS
—
Operating cash flow
$-2.53M
Free cash flow
$-2.81M
Fetching…
Sources
Revenue
$12.88M
Net income
$-1.98M
Diluted EPS
—
Operating cash flow
$-3.54M
Free cash flow
$-4.05M
Fetching…
Sources
Revenue
$11.37M
Net income
$-3.78M
Diluted EPS
—
Operating cash flow
$-1.23M
Free cash flow
$-1.50M
Fetching…
Sources
Revenue
$9.43M
Net income
$-4.15M
Diluted EPS
—
Operating cash flow
$-702.00K
Free cash flow
$-757.00K
Fetching…
Sources
Revenue
$14.22M
Net income
$-4.63M
Diluted EPS
—
Operating cash flow
$-2.94M
Free cash flow
$-3.18M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $2.94
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $12.0M. Interest coverage -1.2x.
Net debt
$12.01M
Interest coverage
-1.15x
Apyx Medical Corporation's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
APYX
BASELINE
Apyx Medical Corporation
Total debt $39.63M Interest coverage -1.15x This is the baseline the peer rows are being compared against.
Total debt $6.36M Interest coverage -18.28x Neither company has much profit cushion over interest right now.
Total debt $16.27M Interest coverage -2.98x Neither company has much profit cushion over interest right now.
Total debt $4.45M Interest coverage 3.42x This peer still has a real interest-payment cushion, while APYX does not.
What you should know
The case for and against APYX
1 Reward
1 Risk
Rewards
-
Revenue grew 12.7% last year.
Risks
-
Return on equity was -90.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-14.55x
P/B
8.45x
P/S
2.12x
EV/EBITDA
-51.30x
PEG ratio
0.59x
Profitability
How much profit each dollar creates
Gross margin
63.5%
Operating margin
-13.0%
Net margin
-14.8%
ROE
-90.7%
ROA
-3.7%
Health
Liquidity and balance-sheet strength
Debt / equity
3.57x
Current ratio
5.68x
Quick ratio
4.41x
Total debt
$39.63M
Total cash
$27.62M
Growth
How the business has been compounding
Revenue TTM
$59.57M
Revenue 5Y CAGR
2.2%
EPS TTM
-0.19
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-8.23M
Free CF TTM
$-9.12M
FCF margin
-15.3%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—